Passage Bio (PASG) has shared an announcement.
Passage Bio, Inc. has announced encouraging developments in its FDA interactions regarding PBFT02, a potential treatment for frontotemporal dementia in patients with C9orf72 gene mutations. The company is set to amend its ongoing study protocol to include this new patient group and plans to start dosing in the first half of 2025. These forward-looking statements are inherently uncertain and carry risks that could impact the company’s stock price, emphasizing that these projections are subject to change.
See more data about PASG stock on TipRanks’ Stock Analysis page.
